MIRA Pharmaceuticals (NASDAQ:MIRA) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
MIRA Pharmaceuticals

BRIEF

published on 05/28/2025 at 14:35, 6 months 7 days ago

MIRA Pharmaceuticals Advances in Clinical Trials and SKNY Acquisition

MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain SKNY Acquisition BIO Convention
PRESS RELEASE

published on 05/28/2025 at 14:30, 6 months 7 days ago

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
MIRA Pharmaceuticals to engage in BIO One-on-One Partnering™ meetings at BIO International Convention 2025, advancing Ketamir-2 Phase 1, neuropathic pain study, and SKNY acquisition filings

MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain SKNY Acquisition BIO International Convention 2025
BRIEF

published on 05/08/2025 at 14:05, 6 months 27 days ago

MIRA Pharmaceuticals Announces Strategic Acquisition of SKNY

Shareholder Approval Enterprise Value MIRA Pharmaceuticals SKNY Acquisition Therapeutic Markets
PRESS RELEASE

published on 05/08/2025 at 14:00, 6 months 27 days ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review
MIRA Pharmaceuticals, Inc. announces board approval for strategic acquisition of SKNY Pharmaceuticals targeting obesity and nicotine dependence. $5 million contribution from SKNY. Merger subject to shareholder approval

Acquisition Obesity MIRA Pharmaceuticals SKNY Pharmaceuticals Nicotine Dependence
BRIEF

published on 05/06/2025 at 14:05, 6 months 29 days ago

MIRA Pharmaceuticals Announces Absence of Neurotoxicity in Ketamir-2 Study

Phase I Trial MIRA Pharmaceuticals Ketamir-2 NMDA Receptor Neurotoxicity Study
PRESS RELEASE

published on 05/06/2025 at 14:00, 6 months 29 days ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
MIRA Pharmaceuticals announces positive preclinical results for oral NMDA receptor antagonist Ketamir-2, showing no brain toxicity. Phase I clinical trial ongoing

Phase I Clinical Trial Preclinical Results MIRA Pharmaceuticals Ketamir-2 Oral NMDA Receptor Antagonist
BRIEF

published on 04/23/2025 at 14:05, 7 months 11 days ago

MIRA Pharmaceuticals Announces Promising Results for Ketamir-2 Topical Formulation

FDA Fast Track Ketamir-2 Topical Formulation In Vitro Testing Pain Relief Market
PRESS RELEASE

published on 04/23/2025 at 14:00, 7 months 11 days ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
MIRA Pharmaceuticals announces completion of IVRT for topical Ketamir-2 formulation in pain-related conditions, aiming to address market needs and regulatory considerations

MIRA Pharmaceuticals Neuropathic Pain Topical Formulation IVRT FDA Guidance
BRIEF

published on 04/16/2025 at 14:05, 7 months 18 days ago

MIRA Pharmaceuticals Reports Promising Ketamir-2 Data for Diabetic Neuropathy

Clinical Trials MIRA Pharmaceuticals Ketamir-2 Diabetic Neuropathy Non-Opioid Treatments
PRESS RELEASE

published on 04/16/2025 at 14:00, 7 months 18 days ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
MIRA Pharmaceuticals announces strong efficacy of Ketamir-2 in diabetic neuropathy model, offering potential breakthrough treatment for patients. Phase IIa trial planned

Clinical Trial MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Diabetic Neuropathy

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 32 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 37 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 7 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 2 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 7 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 3 hours 36 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 16 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 41 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 52 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 56 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 13 hours 7 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 22 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 23 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE